Transcriptional changes common to human cocaine, cannabis and phencyclidine abuse.
A major goal of drug abuse research is to identify and understand drug-induced changes in brain function that are common to many or all drugs of abuse. As these may underlie drug dependence and addiction, the purpose of the present study was to examine if different drugs of abuse effect changes in gene expression that converge in common molecular pathways. Microarray analysis was employed to assay brain gene expression in postmortem anterior prefrontal cortex (aPFC) from 42 human cocaine, cannabis and/or phencyclidine abuse cases and 30 control cases, which were characterized by toxicology and drug abuse history. Common transcriptional changes were demonstrated for a majority of drug abuse cases (N = 34), representing a number of consistently changed functional classes: Calmodulin-related transcripts (CALM1, CALM2, CAMK2B) were decreased, while transcripts related to cholesterol biosynthesis and trafficking (FDFT1, APOL2, SCARB1), and Golgi/endoplasmic reticulum (ER) functions (SEMA3B, GCC1) were all increased. Quantitative PCR validated decreases in calmodulin 2 (CALM2) mRNA and increases in apolipoprotein L, 2 (APOL2) and semaphorin 3B (SEMA3B) mRNA for individual cases. A comparison between control cases with and without cardiovascular disease and elevated body mass index indicated that these changes were not due to general cellular and metabolic stress, but appeared specific to the use of drugs. Therefore, humans who abused cocaine, cannabis and/or phencyclidine share a decrease in transcription of calmodulin-related genes and increased transcription related to lipid/cholesterol and Golgi/ER function. These changes represent common molecular features of drug abuse, which may underlie changes in synaptic function and plasticity that could have important ramifications for decision-making capabilities in drug abusers.
Lehrmann
Elin
E
Cellular Neurobiology Research Branch and Chemistry and Drug Metabolism Section, National Institute on Drug Abuse (NIDA) Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland, United States of America. elehrman@intra.nida.nih.gov
Colantuoni
Carlo
C
Deep-Soboslay
Amy
A
Becker
Kevin G
KG
Lowe
Ross
R
Huestis
Marilyn A
MA
Hyde
Thomas M
TM
Kleinman
Joel E
JE
Freed
William J
WJ
D000328:Adult; D001344:Autopsy; D002147:Calmodulin / Q000235:genetics; D016022:Case-Control Studies; D002784:Cholesterol / Q000378:metabolism; D019970:Cocaine-Related Disorders / Q000235:genetics* / Q000378:metabolism; D004721:Endoplasmic Reticulum / Q000235:genetics; D005260:Female; D006056:Golgi Apparatus / Q000235:genetics; D006801:Humans; D050356:Lipid Metabolism / Q000235:genetics; D008297:Male; D002189:Marijuana Abuse / Q000235:genetics* / Q000378:metabolism; D020411:Oligonucleotide Array Sequence Analysis; D010623:Phencyclidine Abuse / Q000235:genetics* / Q000378:metabolism; D016133:Polymerase Chain Reaction; D017397:Prefrontal Cortex / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D014158:Transcription, Genetic; D055815:Young Adult
D002147:Calmodulin; D012333:RNA, Messenger; D002784:Cholesterol